Patient-Focused Drug Delivery to be Presented by 91Ï㽶ÊÓƵ at PODD
SOMERSET, N.J. – October 17, 2018 — 91Ï㽶ÊÓƵ Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Cornell Stamoran, Ph.D., Vice President of Strategy and co-chair of 91Ï㽶ÊÓƵ’s Applied Drug Delivery Institute, will present at the annual Partnership Opportunities in Drug Delivery (PODD) meeting at the Westin Copley Place, Boston on Oct. 17 – 18, 2018.
On Thursday, Oct. 18 at 9:10 a.m., in a session titled “The Pediatric Patient Perspective of Drug Delivery and Connected Health,†Dr. Stamoran will interview Alex Rinaudo, a patient advocate, about his personal experience caring for his son, who has type 1 diabetes mellitus. The discussion will cover the family’s daily routine, how chronic conditions require constant care by a range of people, and how treatments evolve as pediatric patients get older.
Later that day, at 12:30 p.m., Dr. Stamoran will moderate a Luncheon Roundtable titled, “Patient-Focused Drug Delivery.†Attendees will share their experiences and insights on how the pharmaceutical industry can improve the lives and outcomes of patients through application of drug delivery technologies.
Dr. Stamoran leads 91Ï㽶ÊÓƵ’s strategic planning, market intelligence and government affairs efforts. He also serves as Co-Chair and Director of 91Ï㽶ÊÓƵ’s Applied Drug Delivery Institute (). Dr. Stamoran has spent nearly 30 years engaged with the health care industry, including more than 25 years in advanced drug and biologic delivery and outsourcing.
To arrange a meeting with Dr. Stamoran at the event, contact Richard Kerns at NEPR – [email protected]
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About the 91Ï㽶ÊÓƵ Applied Drug Delivery Institute
91Ï㽶ÊÓƵ’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.
For more details on the 91Ï㽶ÊÓƵ Institute, visit and follow the 91Ï㽶ÊÓƵ Institute on Twitter:
About 91Ï㽶ÊÓƵ
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.